α-Glucosidase-IN-126
α-Glucosidase-IN-126 is a selective and competitive α-glucosidase inhibitor with an IC50 of 0.2 μM and a Ki of 200 nM. α-Glucosidase-IN-126 blocks carbohydrate hydrolysis, inhibits bovine serum albumin glycation, and dose-dependently reduces blood glucose in a diabetic zebrafish model. α-Glucosidase-IN-126 shows minimal cytotoxicity toward normal fibroblasts at low concentrations. α-Glucosidase-IN-126 can be used for research on type 2 diabetes.
For research use only. We do not sell to patients.
- Formula: C33H26N4O2S
- Molecular Weight:542.65
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
α‑glucosidase 0.2 μM (IC50) |
In Vitro
α-Glucosidase-IN-126 (compound 9b) inhibits Saccharomyces cerevisiae α-glucosidase with an IC50 of 0.2 μM, and produces only 13.2% inhibition of bacterial α-amylase, indicating its selectivity for α-glucosidase over α-amylase[1].
α-Glucosidase-IN-126 (0-400 nM) is a competitive α-glucosidase inhibitor with a Ki of 200 nM[1].
α-Glucosidase-IN-126 (31.2-500.0 μg/mL; 72 h incubation; 24 h dialysis) inhibits BSA glycation, with an inhibition rate of 89.0% at 31.2 μg/mL and 93-97% at 125.0-500.0 μg/mL[1].
α-Glucosidase-IN-126 (10-100 μM; 72 h) exhibited minimal cytotoxicity against NIH-3T3 cells, with cell viability of approximately 90% and 70%, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:NIH-3T3 fibroblast cells
-
Concentration:10, 25, 50, 100 μM
-
Incubation Time:72 h at 37 °C
-
Result:Exhibited minimal cytotoxicity at low concentrations, maintaining approximately 90% cell viability at 10 μM and approximately 70% cell viability at 25 μM.
A marked reduction in cell viability was observed only at substantially higher concentrations (50-100 μM).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:AB strain (male, 7 months, 0.06 g)[1]
-
Dosage:0.005 mg/mL, 0.010 mg/mL, 0.015 mg/mL, 0.020 mg/mL
-
Administration:immersion; from day 14 to day 18 and again from day 19 to day 21
-
Result:Reduced blood glucose in a dose-dependent manner: at 0.005 mg/mL, blood glucose was 189.5 mg/dL; at 0.010 mg/mL, 151.7 mg/dL; at 0.015 mg/mL, 103.67 mg/dL; at 0.020 mg/mL, 80.67 mg/dL.
Chemical Information
-
Molecular Weight 542.65
-
Formula C33H26N4O2S
-
SMILES
O=C(C1=CC=C(C=C1)NC(CSC2=NC(C3=CC=CC=C3)=C(N=N2)C4=CC=CC=C4)=O)/C=C/C5=CC=CC=C5C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
How to Select a Suitable Non-Mouse Animal Model
Selecting a suitable non-mouse animal model is a structured decision based on the research question, required anatomy or physiology, disease mechanism, endpoint feasibility, translational relevance, and ethical justification. Non-mouse models are preferred when mice cannot reproduce key human-relevant features, such as organ size, surgical anatomy, cardiovascular physiology, neuroanatomy, immune features, pharmacology, toxicology, or long-term clinical procedures. Candidate species may include rats, rabbits, guinea pigs, ferrets, zebrafish, pigs, sheep, goats, dogs, cats, horses, and non-human primates, but each species must be justified by its specific scientific advantage rather than convenience or tradition. Unresolved questions include how to quantify translational superiority across species, how to balance increased biological relevance against higher ethical burden, and when human-derived systems or new approach methodologies should replace animal use.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)